18F-FDG PET/CT for monitoring of ipilimumab therapy in patients with metastatic melanoma

K Ito, R Teng, H Schöder, JL Humm, A Ni… - Journal of Nuclear …, 2019 - Soc Nuclear Med
Immune checkpoint inhibitors (ICIs) are now commonly used to treat patients with metastatic
malignant melanoma. Although concerns have been raised that the inflammatory response …

Prediction of response to immune checkpoint inhibitor therapy using early-time-point 18F-FDG PET/CT imaging in patients with advanced melanoma

SY Cho, EJ Lipson, HJ Im, SP Rowe… - Journal of Nuclear …, 2017 - Soc Nuclear Med
The purpose of this study was to evaluate 18F-FDG PET/CT scanning as an early predictor
of response to immune checkpoint inhibitors (ICIs) in patients with advanced melanoma …

Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab

H Anwar, C Sachpekidis, J Winkler… - European journal of …, 2018 - Springer
Purpose Evaluation of response to immunotherapy is a matter of debate. The aim of the
present study was to evaluate the response of metastatic melanoma to treatment with …

Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study

C Sachpekidis, L Larribere, L Pan, U Haberkorn… - European journal of …, 2015 - Springer
Purpose Ipilimumab is a newly approved immunotherapeutic agent that has been shown to
provide a survival benefit in patients with metastatic melanoma. 18 F-FDG PET/CT has …

Assessing immune organs on 18F-FDG PET/CT imaging for therapy monitoring of immune checkpoint inhibitors: inter-observer variability, prognostic value and …

K Prigent, C Lasnon, E Ezine, M Janson… - European journal of …, 2021 - Springer
Abstract Background Immune checkpoint inhibitors (ICIs) have significantly improved
survival in advanced melanoma. There is a need for robust biomarkers to identify patients …

The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma

C Sachpekidis, H Anwar, J Winkler… - European Journal of …, 2018 - Springer
Purpose The aim of the present study was to assess the value of interim 18 F-FDG PET/CT
performed after the first two cycles of ipilimumab treatment in the prediction of the final …

[HTML][HTML] Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy

PP van de Donk, TT Wind, JS Hooiveld-Noeken… - European Journal of …, 2021 - Springer
Purpose Immune checkpoint inhibitors can induce a T cell–mediated anti-tumor immune
response in patients with melanoma. Visualizing T cell activity using positron emission …

FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment

A Iravani, MM Osman, AM Weppler, R Wallace… - European journal of …, 2020 - Springer
Purpose We aimed to investigate the role of FDG-PET/CT in monitoring of response and
immune-related adverse events (irAEs) following first-line combination-immune checkpoint …

Immune-mediated disease in ipilimumab immunotherapy of melanoma with FDG PET-CT

JW Wachsmann, R Ganti, F Peng - Academic radiology, 2017 - Elsevier
Rationale and Objectives The purposes of this study were to provide a case-based overview
of various immune-mediated side effects detected by 18F-Fluorodeoxyglucose (F-18 FDG) …

Monitoring of patients with metastatic melanoma treated with immune checkpoint inhibitors using PET–CT

A Dimitrakopoulou-Strauss - Cancer Immunology, Immunotherapy, 2019 - Springer
Immune checkpoint inhibitors (ICI) have revolutionized therapy of metastatic melanoma. The
first ICI was ipilimumab, a cytotoxic T lymphocyte-associated Ag 4 (CLTA-4) inhibitor with …